Results 171 to 180 of about 27,592 (211)
VESALIUS keeps revolutionizing medicine: the case of evolocumab in primary prevention. [PDF]
Eur Heart J Cardiovasc PharmacotherGalli M, Sciarretta S, Crea F.
europepmc +1 more source
Unraveling the temporal sequence of coronary atherosclerosis modification with lipid-lowering therapies through intravascular imaging: a narrative review. [PDF]
Front Cardiovasc MedSun M, Yu Z.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Drug Safety, 2009
Treatments with ezetimibe/simvastatin (combined or alone) have been indicated as very promising approaches to strongly reduce cholesterol levels in hyperlipidemic patients.We will discuss the efficacy and safety of ezetimibe/simvastatin and their potential to reduce atheroprogression.
MONTECUCCO, FABRIZIO +2 more
openaire +4 more sources
Treatments with ezetimibe/simvastatin (combined or alone) have been indicated as very promising approaches to strongly reduce cholesterol levels in hyperlipidemic patients.We will discuss the efficacy and safety of ezetimibe/simvastatin and their potential to reduce atheroprogression.
MONTECUCCO, FABRIZIO +2 more
openaire +4 more sources
2011
Ezetimibe is a drug substance which can be used for lowering low-density lipoprotein cholesterol. Its crystal form and polymorphism have been determined using X-ray diffraction and thermal methods. Quantitative and qualitative analysis of Ezetimibe as well as study of its impurities and degradations were summarized in this chapter.
Maria L A D, Lestari +2 more
openaire +3 more sources
Ezetimibe is a drug substance which can be used for lowering low-density lipoprotein cholesterol. Its crystal form and polymorphism have been determined using X-ray diffraction and thermal methods. Quantitative and qualitative analysis of Ezetimibe as well as study of its impurities and degradations were summarized in this chapter.
Maria L A D, Lestari +2 more
openaire +3 more sources
Expert Opinion on Investigational Drugs, 2002
Ezetimibe is a cholesterol absorption inhibitor that significantly lowers low- density lipoprotein cholesterol (LDL-C), and favourably affects triglyceride and high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins.
openaire +2 more sources
Ezetimibe is a cholesterol absorption inhibitor that significantly lowers low- density lipoprotein cholesterol (LDL-C), and favourably affects triglyceride and high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins.
openaire +2 more sources
Journal of Pharmaceutical and Biomedical Analysis, 2015
The aminolysis of ezetimibe (1) and the structurally similar (3R*,4S*)-(4-fluorophenyl)-4-(4-hydroxyphenyl)-3-methylazetidin-2-one (4a) giving the corresponding β-aminoamides 2a-d and 5a-c was studied spectrophotometrically under pseudo-first order conditions in aqueous butylamine, 3-methoxypropylamine, 2-methoxyethylamine and 2-hydroxyethylamine ...
Jana, Baťová +2 more
openaire +2 more sources
The aminolysis of ezetimibe (1) and the structurally similar (3R*,4S*)-(4-fluorophenyl)-4-(4-hydroxyphenyl)-3-methylazetidin-2-one (4a) giving the corresponding β-aminoamides 2a-d and 5a-c was studied spectrophotometrically under pseudo-first order conditions in aqueous butylamine, 3-methoxypropylamine, 2-methoxyethylamine and 2-hydroxyethylamine ...
Jana, Baťová +2 more
openaire +2 more sources
DMW - Deutsche Medizinische Wochenschrift, 2004
H, Meyer Zu Schwabedissen, H K, Kroemer
openaire +2 more sources
H, Meyer Zu Schwabedissen, H K, Kroemer
openaire +2 more sources